This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG). Subjects with myocardial ischaemic syndromes (MIS) will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy, while the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later. Six month after CABG, CRP will be used to evaluate inflammation, and echocardiography and coronary CTA will be used to evaluate cardiovascular function.
Male or female ≥ 18 years of age
Patients are ready to undergo coronary artery bypass grafting (CABG) with 1 month;
Participate voluntarily and sign an informed consent
None
Parallel
PCSK9 inhibitor
Drugthe experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
Statin
Drugthe control group will receive standard statin therapy.
Major Adverse Cardiovascular and Cerebrovascular Events
Major Adverse Cardiovascular and Cerebrovascular Events include cardiac death, reinfarction, emergency coronary revascularization and stroke
C-reactive protein
Peripheral blood C-reactive protein
Click on the lead sponsor to view all of their trials.
Nanjing Medical University
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Beijing Anzhen Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
